New hope for hard-to-treat melanoma: drug duo aims to outsmart resistance
NCT ID NCT05764395
First seen Apr 29, 2026 · Last updated Jun 19, 2026 · Updated 12 times
Summary
This study tests whether combining two drugs, rigosertib and pembrolizumab, can shrink tumors in people with advanced melanoma that no longer responds to standard immunotherapy. The trial enrolls about 7 adults whose melanoma has spread or cannot be surgically removed. The goal is to see if this combination can control the cancer when other treatments have failed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.